

# Idiopathic Inflammatory Myopathies - Lessons Learned from Animal Models

Ali Maisam Afzali\*

Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, Germany

\*Corresponding author: Ali Maisam Afzali, Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany, Tel +49 8941404630; E-mail: [ali.afzali@tum.de](mailto:ali.afzali@tum.de)

Received Date: 26 March, 2018; Accepted Date: 16 April, 2018; Published Date: 27 April, 2018

Idiopathic Inflammatory Myopathies (IIM) encompass a rare group of (auto)immune mediated muscle diseases characterized by muscle weakness and mononuclear muscle cell infiltrates. Since its first description, research has focused on describing effector and target cell interaction [1-4]. The immunobiological capacity of muscle cells has become increasingly clear over the last few decades. Skeletal Muscle Cells (SkMCs) are perfectly suited to function as non-professional Antigen-presenting Cells (APCs) by expressing MHC I/II and costimulatory molecules as well as secreting soluble molecules like cytokines and chemokines [5]. However, there is an ongoing debate about the role of SkMCs in the pathophysiology of IIMs.

Research in the field of immunology has gained fundamental insights into pathophysiological processes on the basis of experimental animal models. In the context of neuroimmunological diseases like Multiple Sclerosis (MS), immunological animal models have helped to pave the way for novel therapeutic approaches [6]. In IIMs, there is still a lack in an animal model mimicking phenotypical, histopathological and immunological features of IIMs. Although genetically, infectious or immunologically induced models have been already proposed, all of these were only partially able to represent certain aspects of IIMs [7].

Genetically induced models have highlighted the role of non-immune mechanisms in the pathophysiology of IIMs. Especially for Spontaneous Inclusion Body Myositis (sIBM), conditional Knock-out Models (KO models) with in-tracellular deposits like Amyloid Precursor Protein (APP) or phosphorylated tau were able to resemble phenotypical features of myopathies [8-12]. Similar results were obtained from a Major Histocompatibility Complex (MHC)-I KO-model accompanied by increased levels of endoplasmic reticulum stress markers [13-14]. Up to now, most of the genetically induced models lack of histopathological signs of mononuclear cell infiltrates, which is an important finding in IIMs [7]. Infectious mediated murine models resemble an acute monophasic systemic syndrome consisting of myositis, tendinitis and myocarditis with a critically severe disease course and

a high mortality rate [7]. In contrast, immunologically mediated models induced by immunization with muscle homogenates or a muscle specific protein showed histopathological aspects of IIMs like infiltrating CD8+ T cells and muscle fiber surrounding cytokines or chemokines creating an immunological microenvironment. However, up to now clinical signs of myopathy were absent in those models [7].

Since our group has gained experience in Experimental Auto-immune Encephalomyelitis (EAE), the established animal model for MS, we put effort in establishing an immunological model fulfilling all the aforementioned features of IIMs [6-7]. On the example of Sugihara and colleagues and their C-protein Induced Model (CIM) [15], we are immunizing mice with fragments of the C-protein in order to resemble phenotypical and histopathological signs of IIMs [7]. This will be a critical step in order to test potential molecules in the context of this model.

During the last decade, our group has focused on two-pore domain potassium channels (K2P-channels), a certain family of potassium channels formerly termed as "leak channels", in the context of neuroimmunological disease like MS. We were able to show a modulating effect of certain K2P-channels in the disease course of EAE by influencing effector functions of CD4+ and CD8+ T cells or target cells like endothelial cells [16-18]. Recently, we were able to show that different K2P-channels are functionally expressed in SkMCs with an impact on muscle cell differentiation and electrophysiological parameters like potassium current, resting membrane potential and consequently calcium influx [19]. In the context of IIMs, we are interested in the influence of K2P-channels on the aforementioned immunobiological functions of SkMCs with a tendency of anti-inflammatory properties (data not published). Established immunological models are critically necessary to prove this hypothesis with the aid of K2P-KO mice.

However, there is still a long way to go until these goals can be achieved. Gladly, research on IIMs has become more popular

over the last few decades [7]. Future investigations should take putative approaches like humanized animal models [20-21] or the concept of exercise/injury induced muscle immunology [22-24] into account in order to pave the way to enlighten the pathophysiology of IIMs and enable putative pharmacological treatments.

## References

1. Dalakas MC (2010) Inflammatory muscle diseases: a critical review on pathogenesis and therapies. *Curr Opin Pharmacol* 10: 346-352.
2. Dalakas MC (2011) Review: an update on inflammatory and autoimmune myopathies. *Neuropathol Appl Neurobiol* 37: 226-242.
3. Dorph C, Lundberg IE (2002) Idiopathic inflammatory myopathies - myositis. *Best Pract Res Clin Rheumatol* 16: 817-832.
4. Targoff IN, Miller FW, Medsger TA Jr, Oddis CV (1997) Classification criteria for the idiopathic inflammatory myopathies. *Curr Opin Rheumatol* 9: 527-535.
5. Afzali AM, Müntefering T, Wiendl H, Meuth SG, Ruck T (2018) Skeletal muscle cells actively shape (au-to)immune responses. *Autoimmun Rev* 17: 518-529.
6. Bittner S, Afzali AM, Wiendl H, Meuth SG (2014) Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. *J Vis Exp* 86: e51275.
7. Afzali AM, Ruck T, Wiendl H, Meuth SG (2017) Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock? *Autoimmun Rev* 16: 478-494.
8. Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, et al. (2002) Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. *Proc Natl Acad Sci U S A* 99: 6334-6339.
9. Sugarman MC, Kitazawa M, Baker M, Caiozzo VJ, Querfurth HW, et al. (2006) Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. *Neurobiol Aging* 27: 423-432.
10. Kitazawa M, Green KN, Caccamo A, LaFerla FM (2006) Genetically augmenting A $\beta$ 42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. *Am J Pathol* 168:1986-1997.
11. Moussa CE, Fu Q, Kumar P, Shtifman A, Lopez JR, et al. (2006) Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. *FASEB J* 20: 2165-2167.
12. Shtifman A, Ward CW, Laver DR, Bannister ML, Lopez JR, et al. (2010) Amyloid-beta protein impairs Ca<sup>2+</sup> release and contractility in skeletal muscle. *Neurobiol Aging* 31: 2080-2190.
13. Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, et al. (2000) Conditional upregulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. *Proc Natl Acad Sci U S A* 97: 9209-9214.
14. Li CK, Knopp P, Moncrieffe H, Singh B, Shah S, et al. (2009) Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. *Am J Pathol* 175: 1030-1040.
15. Sugihara T, Sekine C, Nakae T, Kohyama K, Harigai M, et al. (2007) A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. *Arthritis Rheum* 56: 1304-1314.
16. Bittner S, Meuth SG, Gobel K, Melzer N, Herrmann AM, et al. (2009) TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. *Brain* 132: 2501-16.
17. Bittner S, Bobak N, Herrmann AM, Göbel K, Meuth P, et al. (2010) Upregulation of K2P5.1 potassium channels in multiple sclerosis. *Ann Neurol* 68: 58-69.
18. Bittner S, Ruck T, Schuhmann MK, Herrmann AM, Moha ou Maati H, et al. (2013) Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS. *Nat Med* 19: 1161-1165.
19. Afzali AM, Ruck T, Herrmann AM, Iking J, Sommer C, et al. (2016) The potassium channels TASK2 and TREK1 regulate functional differentiation of murine skeletal muscle cells. *Am J Physiol Cell Physiol* 311: C583-C595.
20. Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, et al. (2014) Development and function of human innate immune cells in a humanized mouse model. *Nat Biotechnol* 32: 364-372.
21. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL (2012) Humanized mice for immune system investigation: progress, promise and challenges. *Nat Rev Immunol* 12: 786-798.
22. Pedersen BK, Hoffman-Goetz L (2000) Exercise and the immune system: regulation, integration, and adaptation. *Physiol Rev* 80: 1055-1081.
23. Peake JM, Neubauer O, Della Gatta PA, Nosaka K (2017) Muscle damage and inflammation during recovery from exercise. *J Appl Physiol* 122: 559-570.
24. Allen J, Sun Y, Woods JA (2015) Exercise and the Regulation of Inflammatory Responses. *Prog Mol Biol Transl Sci* 135: 337-354.